{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-150889","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.771357+00:00","generated_at":"2026-06-25T13:38:12.270541+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alaunos Therapeutics reports Q1 net loss of $9.8M; first patient dosed in TCR-T Library trial","bullets":["Net loss $9.8M ($0.05/sh) vs $21.6M ($0.10) in Q1 2021; cash $68.3M.","First patient dosed in TCR-T Library Phase 1/2 trial targeting KRAS, TP53, EGFR mutations across six solid tumors.","R&D expenses $5.6M (-58%), G&A $3.5M (-57%), operating cash burn $7.8M (-49%).","Preclinical data on mbIL-15 presented at ASGCT; IND expected H2 2023.","Initial clinical data expected H2 2022; cash runway into Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-150889","json":"https://secwatch.observer/filing/0001193125-22-150889.json","markdown":"https://secwatch.observer/filing/0001193125-22-150889.md","text":"https://secwatch.observer/filing/0001193125-22-150889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/0001193125-22-150889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/d359627d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T13:38:12.270541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"decf001650b9fb11d7d43c3b8e21a45a9b6dd53e","claim":"Alaunos Therapeutics, Inc. reported three months ended March 31, 2022 results: net income Net loss was $9.8 million, or $(0.05) per share, EPS $(0.05) per share.","evidence_excerpt":"Alaunos Therapeutics, Inc. issued a press release announcing its financial condition and results of operations for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/0001193125-22-150889-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2022"},{"label":"Net income","value":"Net loss was $9.8 million, or $(0.05) per share"},{"label":"EPS","value":"$(0.05) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}